deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT03478462

Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma (CLOVER-2)

An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain Tumors

Sponsor: Cellectar Biosciences, Inc.

Conditions DIPG Ewing Sarcoma Neuroblastoma Osteosarcoma Pediatric Brain Tumor Pediatric Lymphoma Pediatric Solid Tumor Rhabdomyosarcoma
Interventions CLR 131
Updated 20 times since 2018 Last updated: Mar 25, 2025 Started: Apr 30, 2019 Primary completion: Dec 25, 2025 Completion: Dec 31, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on DIPG and Ewing Sarcoma, this trial is ongoing. The trial is conducted by Cellectar Biosciences, Inc. and has accumulated 20 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Apr 2019 · 3 months · monthly snapshot~Apr 2019 – ~Aug 2019 · 4 months · monthly snapshot~Aug 2019 – ~Oct 2019 · 2 months · monthly snapshot~Oct 2019 – ~Dec 2019 · 2 months · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Jan 2021 · 10 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~Jan 2022 · 4 months · monthly snapshot~Jan 2022 – ~Mar 2023 · 14 months · monthly snapshot~Mar 2023 – ~Jun 2023 · 3 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Apr 2025 · 31 days · monthly snapshot~Apr 2025 – present · 15 months · monthly snapshot

Change History

20 versions recorded

  1. Apr 2025 — Present [monthly]

    Active Not Recruiting PHASE1

    Status: Unknown → Active Not Recruiting

  2. Mar 2025 — Apr 2025 [monthly]

    Unknown PHASE1

    Status: Active Not Recruiting → Unknown

  3. Sep 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE1

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Jun 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

▶ Show 15 earlier versions

  1. Mar 2023 — Jun 2023 [monthly]

    Recruiting PHASE1

  2. Jan 2022 — Mar 2023 [monthly]

    Recruiting PHASE1

  3. Sep 2021 — Jan 2022 [monthly]

    Recruiting PHASE1

  4. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  5. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1

  6. Mar 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  7. Feb 2020 — Mar 2020 [monthly]

    Recruiting PHASE1

  8. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE1

  9. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE1

  10. Oct 2019 — Dec 2019 [monthly]

    Recruiting PHASE1

  11. Aug 2019 — Oct 2019 [monthly]

    Recruiting PHASE1

  12. Apr 2019 — Aug 2019 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  13. Jan 2019 — Apr 2019 [monthly]

    Not Yet Recruiting PHASE1

  14. Jun 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE1

  15. Apr 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cellectar Biosciences, Inc.
Data source: Cellectar Biosciences, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations